-
Stay Connected
Get the latest news on exciting speakers, workshops & learning opportunities at ISDE 2021.
Subscribe for Updates
Advanced esophageal squamous cell carcinoma (ESCC) has historically been difficult to control because many patients present with metastatic or unresectable disease. Cytotoxic chemotherapy can reduce tumor burden, yet responses may be temporary and treatment tolerance can be limited by dysphagia, malnutrition, pain, and coexisting illness.
Immune checkpoint inhibitors have changed the treatment discussion. By blocking inhibitory signals involving PD-1, PD-L1, or CTLA-4, these medicines can restore antitumor T-cell activity. Their benefits are meaningful for selected patients, although response patterns, biomarker results, and toxicity risks require careful interpretation.
Treatment decisions should be based on pathology, disease extent, performance status, nutritional condition, organ function, and patient goals. Findings presented through specialist societies and international congresses such as ISDE 2021 continue to support multidisciplinary evaluation of complex esophageal disease.
ESCC develops in an immune environment shaped by chronic inflammation, tobacco and alcohol exposure, viral factors in some regions, and substantial genetic diversity. Tumor cells may exploit PD-1/PD-L1 signaling to suppress immune recognition. Checkpoint blockade interrupts that signal, allowing immune cells to attack malignant tissue.
The clinical value of immunotherapy differs from conventional chemotherapy. Some patients experience durable disease control after an early period of stable disease, while others progress quickly. Radiographic assessment therefore needs clinical context, especially when symptoms, inflammatory changes, or atypical response patterns complicate interpretation.
The strongest evidence for advanced disease supports combining a checkpoint inhibitor with platinum-based chemotherapy and a fluoropyrimidine. Trials such as KEYNOTE-590 and CheckMate 648 demonstrated improved outcomes in appropriate patients with advanced esophageal cancer, with particularly important benefits reported in ESCC and in groups defined by PD-L1 expression.
Nivolumab with chemotherapy, nivolumab plus ipilimumab, and pembrolizumab-based combinations may be considered depending on regional approvals, PD-L1 testing, contraindications, and available expertise. Treatment guidelines should be checked regularly because indications and preferred regimens continue to evolve.
| Treatment approach | Common clinical setting | Important considerations |
|---|---|---|
| Checkpoint inhibitor plus chemotherapy | Initial treatment for unresectable or metastatic ESCC | Offers rapid cytoreduction from chemotherapy with potential immune durability |
| Checkpoint inhibitor alone | Selected patients with biomarker support or chemotherapy intolerance | May be better tolerated but can produce slower or less predictable tumor shrinkage |
| Dual checkpoint blockade | Selected first-line patients in approved settings | Can increase immune toxicity and requires careful patient selection |
| Later-line immunotherapy | Disease progression after systemic treatment | Benefit depends on prior therapy, PD-L1 status, and local authorization |
PD-L1 testing is commonly reported using the combined positive score (CPS) or tumor proportion score (TPS), depending on the assay and treatment regimen. A higher score may enrich the population likely to benefit, but PD-L1 is an imperfect predictor. A low score does not always exclude benefit, and a high score cannot guarantee response.
Performance status, autoimmune disease, transplant history, uncontrolled infection, steroid dependence, and organ impairment should be reviewed before treatment. Severe malnutrition and dehydration can also affect tolerance. In older adults with several comorbidities, broader perioperative and supportive planning is valuable; discussions of surgical care for older patients illustrate why functional assessment should accompany disease-focused decisions.
Immune-related adverse events can involve almost any organ. Common concerns include rash, diarrhea or colitis, thyroid dysfunction, hepatitis, pneumonitis, nephritis, and adrenal or pituitary inflammation. Symptoms may appear during treatment or weeks after the last dose, so patients need clear instructions for reporting new problems.
Management depends on severity and the affected organ. Treatment may involve holding immunotherapy, laboratory monitoring, specialist referral, corticosteroids, or other immunosuppressive therapy. Fever, shortness of breath, severe diarrhea, jaundice, confusion, and rapidly worsening weakness require urgent assessment because delayed recognition can result in serious complications.
Systemic therapy works best when paired with active symptom management. Dysphagia may require dietary modification, nutritional support, endoscopic intervention, or carefully selected stenting. Pain control, smoking cessation, psychosocial support, and early palliative care can improve quality of life alongside anticancer treatment.
Radiation therapy or surgery may have a role in selected situations, such as bleeding, obstruction, oligometastatic disease, or durable local control after systemic response. These decisions should be made by a team involving medical oncology, radiation oncology, gastroenterology, surgery, radiology, pathology, nutrition, and specialist nursing.
Before treatment begins, clinicians should confirm histology and stage, obtain baseline imaging, assess PD-L1 status where relevant, and document renal, hepatic, endocrine, and pulmonary function. Medication review is essential, particularly for corticosteroids and other immunosuppressants that may influence immune activation or toxicity management.
During therapy, response assessment should combine scans with swallowing function, weight, pain, nutritional intake, and performance status. Continuing treatment requires evidence of benefit and acceptable toxicity. Progression should prompt review of adherence, imaging timing, mixed response, and opportunities for clinical trials rather than an automatic assumption that every lesion represents treatment failure.
Immunotherapy has created durable treatment opportunities for some people with advanced ESCC, but its success depends on thoughtful selection, rapid toxicity management, and coordinated supportive care. Clinicians and learners can deepen their understanding through specialist congress resources, updated guidelines, and ongoing clinical research in esophageal oncology.